Target intelligence / Profile preview

Pre–T-cell antigen receptor alpha (PTCRA)

Target
PTCRA
Molecular classification
Receptor, Type I transmembrane protein, Member of the immunoglobulin (Ig) superfamily
01

Overview

Pre–T-cell antigen receptor alpha (PTCRA) is a single-pass type I transmembrane protein and a member of the immunoglobulin superfamily expressed in immature thymocytes. It forms a key part of the pre-T-cell receptor (pre-TCR) complex by covalently associating with the T-cell receptor beta (TCRβ) chain and the CD3 signaling complex; this complex is essential for early T-cell development in the thymus. PTCRA’s primary function is to permit survival, proliferation, and differentiation of thymocytes with successful TCRβ rearrangement, regulate TCRβ allelic exclusion, and allow αβ T cell lineage commitment. The receptor operates in a ligand-independent, self-oligomerizing fashion, with signaling dependent on the associated CD3 complex. Deficiency or mutation of PTCRA leads to developmental arrest of αβ T cells and immunodeficiency, while its dysregulation can contribute to certain immune or lymphoproliferative disorders. The gene encoding PTCRA is also known as pT-alpha and is conserved in amniotes. There are no drugs targeting PTCRA, but its function is vital in basic T-cell biology and immunodeficiency research.

Other names
Pre-T-cell antigen receptor alphaPTCRApT-alphapTaPTAPT-ALPHApT-alpha-TCRpre-T-cell receptor alpha chain
02

Mechanism of action

Not applicable due to absence of direct targeting drugs; the molecule’s function is intrinsic to T-cell development rather than as a drug target

03

Biological functions

Essential component of the pre-T-cell receptor (pre-TCR) complexRegulates early T-cell development, especially αβ T cell differentiationMediates survival, proliferation, and differentiation of developing thymocytesControls TCRβ allelic exclusion and initiates TCRα gene rearrangement
04

Disease associations

Immunodeficiencies (notably Immunodeficiency 126)Potential role in T cell acute lymphoblastic leukemia (by analogy to T cell development defects)Possible involvement in cancer (Frontal sinus cancer association)
05

Safety considerations

Genetic disruption or deficiency may result in severe T-cell immunodeficiencyNo direct pharmacological safety data due to lack of drug targeting
06

Interacting drugs

None known or established; no approved drugs directly targeting PTCRA
07

Biomarkers

Expression can serve as a marker for immature T-cells/thymocytes during T-cell developmentLoss or mutation may be used in research as a marker for failed T-cell maturation

Beyond the preview

Go deeper on Pre–T-cell antigen receptor alpha (PTCRA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pre–T-cell antigen receptor alpha (PTCRA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call